γ-Secretase as a target for drug intervention in Alzheimer's disease

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 5, 2004, Pages 709-719

  Harrison, Timothy ^a   Churcher, Ian ^a   Beher, Dirk ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

Secretase; Alzheimer's disease; Amyloid peptide; Aspartyl protease; Notch; Presenilin

Indexed keywords

ACETAMIDE DERIVATIVE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BENZODIAZEPINE DERIVATIVE; BETA SECRETASE; BMS 299897; BRAIN PROTEIN; CAPROLACTAM DERIVATIVE; ESTER DERIVATIVE; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HYDROXYL GROUP; IBUPROFEN; INDOMETACIN; LACTAM DERIVATIVE; LEVO FLURBIPROFEN; LY 374973; LY 411575; LY 450139; MANDELIC ACID DERIVATIVE; METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERIDINE DERIVATIVE; SULFAMIDE DERIVATIVE; SULFONAMIDE; SULFONE DERIVATIVE; SULINDAC SULFIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING SITE; CLINICAL TRIAL; DIARRHEA; DRUG INHIBITION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; NONHUMAN; PROTEIN DEGRADATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; CLINICAL TRIALS, PHASE II; DRUG DESIGN; ENDOPEPTIDASES; HUMANS; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TECHNOLOGY, PHARMACEUTICAL;

EID: 4944262700     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Alzheimer A: Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatrie Psychisch-Gericht/ Med (1907) 64: 146-148.
2. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A: Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein Tau. Proc Natl Acad Sci USA (1988) 85(11):4051-4055.
3. Goedert M, Sisodia SS, Price DL: Neurofibrillary tangles and β-amyloid deposits in Alzheimer's disease. Curr Opin Neurobiol (1991) 1(3):441-447.
4. Glenner GG, Wong CW: Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 120(3):885-890.
5. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA (1985) 82(12):4245-4249.
6. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 325(6106):733-736.
7. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB et al: Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature (1992) 359(6393):322-325.
8. Hardy JA, Higgins GA: Alzheimer's disease: The amyloid cascade hypothesis. Science (1992) 256(5054):184-185.
9. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci (1997) 20(4):154-159.
10. Hardy J: The Alzheimer family of diseases: Many etiologies, one pathogenesis? Proc Natl Acad Sci USA (1997) 94(6):2095-2097.
11. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA (2003) 100(18):10417-10422.
12. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA: Evidence that tumor necrosis factor-α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem (1998) 273(43):27765-27767.
13. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F: Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA (1999) 96(7):3922-3927.
14. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K: Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell (1989) 57(1):115-126.
15. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y et al: β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286(5440):735-741. The first report describing the cloning of BACE-1.
16. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J: Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc Natl Acad Sci USA (2000) 97(4):1456-1460.
17. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K et al: Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature (1999) 402(6761):537-540.
18. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS et al: Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci (1999) 14(6):419-427.
19. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB et al: Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature (1999) 402(6761):533-537.
20. Saunders AJ, Kim T-W, Tanzi RE: BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. Science (1999) 286(5443):1255.
21. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR, Tew DG, Meek TD, Chapman C, Schneider K, Ratcliffe SJ et al: ASP1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site. Mol Cell Neurosci (2000) 16(5):609-619.
22. Yan R, Munzner JB, Shuck ME, Bienkowski MJ: BACE2 functions as an alternative α-secretase in cells. J Biol Chem (2001) 276(36):34019-34027.
23. Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, Teplow DB, Haass C, Walter J: A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem (2002) 81(5):1011-1020.
24. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H: BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc Natl Acad Sci USA (2000) 87(17):9712-9717.
25. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L et al: Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci (2001) 4(3):231-232. Demonstrates that BACE-1 knockout animals are viable in the absence of Aβ peptide production.
26. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R et al: Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med (2003) 9(1):3-4.
27. John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL: Human β-secretase (BACE) and BACE inhibitors. J Med Chem (2003) 46(22):4625-4630.
28. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J et al: Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 17(1):181-190. The first detailed characterization of presenilins in cells and a description of endoproteolytic processing of presenilin 1 into its fragments.
29. Doan A, Thinakaran G, Borchelt DR, Slunt HH, Ratovitsky T, Podlisny M, Selkoe DJ, Seeger M, Gandy SE, Price DL, Sisodia SS: Protein topology of presenilin 1. Neuron (1996) 17(5):1023-1030.
30. Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, Borchelt DR, Sisodia SS: Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem (1997) 272(45):28415-28422. Suggests that presenilins compete for rate-limiting endogenous cellular factors.
31. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 391(6665):387-390. The first demonstration that presenilin expression is required for γ-secretase activity.
32. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoprotsolysis and γ-secretase activity. Nature (1999) 398(6727):513-517. Postulates that presenilin is an aspartyl-type protease on the finding that replacement of either of its two transmembrane Asp residues inactivates γ-secretase.
33. Steiner H, Kostka M, Romig H, Basset G, Pesold B, Hardy J, Capell A, Meyn L, Grim ML, Baumeister R, Fechteler K et al: Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol (2000) 2(11):848-851.
34. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN et al: Presenilin-1 and -2 are molecular targets for β-secretase inhibitors. J Biol Chem (2000) 275(44):34086-34091. This paper, along with references [35•] and [36•], demonstrates that presenilins are the target for γ-secretase inhibitors and therefore form the catalytic center of the enzyme.
35. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB et al: Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 405(6787):689-694. This paper, along with references [34•] and [36•], demonstrates that presemlins are the target for γ-secretase inhibitors and therefore form the catalytic center of the enzyme.
36. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, Rahmati T, Xia W, Selkoe DJ, Wolfe MS: Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol (2000) 2(7):428-434. • This paper, along with references [34•] and [35•], demonstrates that presenilins are the target for γ-secretase inhibitors and therefore form the catalytic center of the enzyme.
37. Wrigley JD, Nunn EJ, Nyabi O, Clarke EE, Hunt P, Nadin A, De Strooper B, Shearman M, Beher D: Conserved residues within the putative active site of γ-secretase differentially influence enzyme activity and inhibitor binding. J Neurochem (2004) 90(6):1312-1328.
38. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song YQ, Rogaeva E, Chen F, Kawarai T, Supala A et al: Nicastrin modulates presenilin-mediated Notch/Glp-1 signal transduction and βAPP processing. Nature (2000) 407(6800):48-54. Description of the identification of nicastrin (purified from presenilin-containing high-molecular-weight complexes) as a co-factor of γ-secretase.
39. Goutte C, Tsunozaki M, Hale VA, Priess JR: Aph-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA (2002) 99(2):775-779. Reports the identification of Aph-1.
40. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, Parks AL et al: Aph-1 and Pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev Cell (2002) 3(1):85-97. Describes the identification of Pen-2 in a functional screen and confirms that both Aph-1 and Pen-2 are required for γ-secretase activity.
41. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C: Reconstitution of β-secretase activity. Nat Cell Biol (2003) 5(5):486-488. This publication, along with references [42•] and [43•], describes the reconstitution of γ-secretase by overexpression of presenilins together with its co-factors. Note that this reference provides the strongest evidence as γ-secretase was overexpressed in yeast that does not contain endogenous γ-secretase activity.
42. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T: The role of presenilin cofactors in the γ-secretase complex. Nature (2003) 422(6930):438-441. This publication, along with references [41•] and [43•], describes the reconstitution of γ-secretase by overexpression of presenilins together with its cofactors.
43. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ: γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1 and Pen-2. Proc Natl Acad Sci USA (2003) 100(11):6382-6387. This publication, along with references [41•] and [42•], describes the reconstitution of γ-secretase by overexpression of presenilins together with its cofactors.
44. Haass C: Take five-BACE and the γ-secretase quartet conduct Alzheimer's amyloid β-peptide generation. EMBO J (2004) 23(3):483-488. Excellent review of the five proteins involved in Aβ production; BACE and the γ-secretase quartet.
45. Hu Y, Fortini ME: Different cofactor activities in γ-secretase assembly: Evidence for a nicastrin-Aph-1 subcomplex. J Cell Biol (2003) 161(4):685-690.
46. LaVoie MJ, Fraering PC, Ostaszewski BL, Ye W, Kimberly WT, Wolfe MS, Selkoe DJ: Assembly of the γ-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem (2003) 278(39):37213-37222.
47. Shirotani K, Edbauer D, Capell A, Schmitz J, Steiner H, Haass C: γ-Secretase activity is associated with a conformational change of nicastrin. J Biol Chem (2003) 278(19):16474-16477.
48. Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, Tomita T et al: A presenilin dimer at the core of the β-secretase enzyme: Insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci USA (2003) 100(22):13075-13080.
49. Fortna RR, Crystal AS, Morais VA, Pijak DS, Lee VM, Doms RW: Membrane topology and nicastrin-enhanced endoproteolysis of Aph-1, a component of the β-secretase complex. J Biol Chem (2004) 279(5):3685-3693.
50. Crystal AS, Morais VA, Pierson TC, Pijak DS, Carlin D, Lee VM, Doms RW: Membrane topology of β-secretase component Pen-2. J Biol Chem (2003) 278(22):20117-20123.
51. Ni CY, Murphy MP, Golde TE, Carpenter G: γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 294(5549):2179-2181.
52. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L, Kim TW: Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J Biol Chem (2002) 277(8):6318-6323.
53. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Edbauer D, Walter J, Steiner H, Haass C: Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Aβ-like peptide. J Biol Chem (2002) 277(47):44754-44759.
54. Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, David G: Syndecan 3 intramembrane proteolysis is presenilin/γ-secretase- dependent and modulates cytosolic signaling. J Biol Chem (2003) 278(49):48651-48657.
55. Kim DY, Ingano LA, Kovacs DM: Nectin-1α, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/β-secretase-like cleavage. J Biol Chem (2002) 277(51):49976-49981.
56. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK: A CBP binding transcriptional repressor produced by the PS1/ε-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell (2003) 114(5):635-645.
57. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Samer S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T et al: A presenilin-1/β- secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J (2002) 21(8):1948-1956.
58. Taniguchi Y, Kim SH, Sisodia SS: Presenilin-dependent 'γ-secretase' processing of deleted in colorectal cancer (DCC). J Biol Chem (2003) 278(33):30425-30428.
59. Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK, Kim DS, Ryu SH, Chao MV, Kim TW: Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem (2003) 278(43):42161-42169.
60. May P, Reddy YK, Herz J: Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem (2002) 277(21):18736-18743.
61. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A et al: A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 398(6727):518-522. First evidence that presenilin/γ-secretase is required for intramembraneous cleavage of the Notch receptor, which mediates Notch signaling.
62. Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, Logeat F: The Notch ligand Delta 1 is sequentially cleaved by an ADAM protease and γ-secretase. Proc Natl Acad Sci USA (2003) 100(13):7638-7643.
63. LaVoie MJ, Selkoe DJ: The Notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments. J Biol Chem (2003) 278(36):34427-34437.
64. Okochi M, Steiner H, Fukumori A, Tanii H, Tomita T, Tanaka T, Iwatsubo T, Kudo T, Takeda M, Haass C: Presenilins mediate a dual intramembranous γ-secretase cleavage of Notch-1. EMBO J (2002) 21(20):5408-5416.
65. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C: Presenilin-dependent γ-secretase processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep (2001) 2(9):835-841.
66. Gu Y, Misonou H, Sato T, Dohmae N, Takio K, Ihara Y: Distinct intramembrane cleavage of the β-amyloid precursor protein family resembling γ-secretase-like cleavage of Notch. J Biol Chem (2001) 276(38):35235-35238.
67. Weidemann A, Eggert S, Reinhard FB, Vogel M, Paliga K, Baier G, Masters CL, Beyreuther K, Evin G: A novel ε-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 41(8):2825-2835.
68. Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature (1998) 393(6683):382-386.
69. Artavanis-Tsakonas S, Matsuno K, Fortini ME: Notch signaling. Science (1995) 268(5208):225-232.
70. Radtke F, Wilson A, MacDonald HR: Notch signaling in T- and B-cell development. Curr Opin Immunol (2004) 16(2):174-179.
71. Radtke F, Wilson A, Mancini SJ, MacDonald HR: Notch regulation of lymphocyte development and function. Nat Immunol (2004) 5(3):247-253.
72. Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M, Kageyama R, Guillemot F, Serup P, Madsen OD: Control of endodermal endocrine development by Hes1. Nat Genet (2000) 24(1):36-44. • Early publication suggesting inhibition of Notch signaling may affect endocrine development.
73. Beher D, Wrigley JD, Nadin A, Evin G, Masters CL, Harrison T, Castro JL, Shearman MS: Pharmacological knock-down of the presenilin 1 heterodimer by a novel γ-secretase inhibitor; Implications for presenilin biology. J Biol Chem (2001) 276(48):45394-45402.
74. Lewis HD, Perez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, Shearman MS: Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry (2003) 42(24):7580-7586. • Detailed study which demonstrates that γ-secretase inhibitors do not discriminate between Notch cleavage and γ-secretase cleavage βAPP.
75. Harrison T, Beher D: γ-Secretase inhibitors - from molecular probes to new therapeutics? Prog Med Chem (2003) 41:99-127.
76. Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJ, Lile JD, Citron M: Fenchylamine sulfonamide inhibitors of amyloid β peptide production by the γ-secretase proteolytic pathway: Potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. J Med Chem (2000) 43(12):2297-2299.
77. Tian G, Ghanekar SV, Aharony D, Shenvi AB, Jacobs RT, Liu X, Greenberg BD: The mechanism of γ-secretase. Multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J Biol Chem (2003) 278(31):28968-28975.
78. Felsenstein, KM: Aβ modulation: The next generation of AD therapeutics. 9th Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, Switzerland (2000):245-249.
79. Dovey HF, John V, Anderson JP, Chen LZ, de Saint AP, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL et al: Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem (2001) 76(1):173-181.
80. Audia JE, Nissen JS, Mabry TE, McDaniel S, Porter WJ, Henry SS, Britton TC, Reel JK, Droste JJ, Mitchell D, Schenk DB et al: Testing the amyloid hypothesis: Optimization and characterization of a novel small molecule functional γ-secretase inhibitor. 228th ACS National Meeting, Philadelphia, PA, USA (2004):MEDI-184.
81. Churcher I, Williams S, Kerrad S, Harrison T, Castro JL, Shearman MS, Lewis HD, Clarke EE, Wrigley JD, Beher D, Tang YS et al: Design and synthesis of highly potent benzodiazepine γ-secretase inhibitors: Preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S) -1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]-[1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement. J Med Chem (2003) 46(12):2275-2278.
82. Owens AP, Nadin A, Talbot AC, Clarke EE, Harrison T, Lewis HD, Reilly M, Wrigley JD, Castro JL: High affinity, bioavailable 3-amino-1,4-benzodiazepine- based γ-secretase inhibitors. Bioorg Med Chem Lett (2003) 13(22):4143-4145.
83. Yan XX, Li T, Rominger CM, Prakash SR, Wong PC, Olson RE, Zaczek R, Li YW: Binding sites of γ-secretase inhibitors in rodent brain: Distribution, postnatal development, and effect of deafferentation. J Neurosci (2004) 24(12):2942-2952.
84. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant KM: The γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther (2003) 305(3):864-871.
85. Wolfe MS, Esler WP, Kimberly WT, Berezovska O, Jack C, Hyman BT: γ-Secretase/presenilin inhibitor causes notch-deficient phenotype in Drosophila. Abst Soc Neurosci (2001):Abs 244.1
86. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C: A γ-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMSO Rep (2002) 3(7):688-694.
87. Lanz TA, Wu H, Landrum CS, Ellerbrock BR, Nye JS, Merchant KM: Reduced Aβ levels in Tg2576 brain, CSF and plasma by potent γ-secretase inhibitors but not by NSAIDs. Abst Soc Neurosci (2003):Abs 729.1.
88. 1-[(7S)-5-methyl-6-oxo-6,7- dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther (2004) 309(1):49-55.
89. May PC, Altstiel LD, Bender MH, Boggs LN, Calligaro DO, Fuson KS: Marked reduction in Aβ accumulation and β amyloid plaque pathology in mice upon chronic treatment with a functional γ-secretase inhibitor. Abst Soc Neurosci (2001):Abs 687.1
90. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP: Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J Biol Chem (2003) 278(46):46107-46116. This paper, along with reference [91•], describes gastrointestinal toxicity associated with certain γ-secretase inhibitors and the Notch-dependent mechanism of toxicity.
91. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz MC, Fine JS, Lee HJ, Zhang L et al: Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 279(13):12876-12882. • This paper, along with reference [90•], describes gastrointestinal toxicity associated with certain γ-secretase inhibitors and the Notch-dependent mechanism of toxicity.
92. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson AP, Tariot P, Zoulnouni P et al: Effect of LY450139, a functional γ-secretase inhibitor, on plasma and cerebrospinal fluid concentrations of Aβ and cognitive functioning in patients with mild to moderate Alzheimer's disease. 50th Annual Meeting American Academy of Neurology, San Francisco, CA, USA (2004):S17.001.
93. 1-42, formation in vitro and in vivo without affecting Notch cleavage in cells.
94. 42 generation. J Biol Chem (2003) 278(20):18664-18670.
95. 42 production by direct modulation of γ-secretase activity. J Biol Chem (2003) 278(34):31831-31837.
96. Phase II multicenter, randomized, double-blind, placebo-controlled study of the effect of daily treatment with MPC-7869 on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type: Myriad Genetics Inc, Salt Lake City, UT, USA. http://www.myriad.com/ pharma/clinicaltrials/alzheimers.htm#phase2.
97. MERCK SHARP & DOHME LTD/MERCK FROSST CANADA & CO (Belanger PC, Collins IJ, Hannam JC, Harrison T, Lewis SJ, Madin A, McIver EG, Nadin AJ, Neduvelil JG, Shearman MS, Smith AL et al): Sulfonamido-substituted bridged bicycloalkyl derivatives. WO-00170677 (2001).
98. MERCK SHARP & DOHME LTD (Collins IJ, Hannam JC, Harrison T, Lewis SJ, Madin A, Sparey TJ, Williams BJ): Sulfamides as γ-secretase inhibitors. WO-00236555 (2002).
99. WYETH/ARQULE INC (Kreft AF, Cole DC, Woller KR, Stock JR, Kutterer KM, Kubrak DM, Mann CW, Moore WJ, Casebier DS): Substituted phenylsulfonamide inhibitors of β amyloid production. WO-03103660 (2003).
100. WYETH/ARQULE INC (Kreft AF, Cole DC, Woller KR, Stock JR, Diamanitis G, Kurbrak DM, Kutterer KM, Moore WJ, Casebier DS): Heterocyclic sulfonamide inhibitors of β amyloid production. WO-02057252 (2002).
101. MERCK & CO INC/BRISTOL-MYERS SQUIBB CO (Smith DW): Novel sulfonamide compounds and uses thereof. WO-00050391 (2000).
102. BRISTOL-MYERS SQUIBB CO (Parker MF, McElhone KE, Mate RA, Bronson JJ, Gai Y, Bergstrom CP, Marcin LR, Macor JE): α-(N-Sulfonamido)acetamide derivatives as β-amyloid inhibitors. WO-03053912 (2003).
103. SCHERING CORP (Josien HB): Sulfonamide derivatives as γ-secretase inhibitors. WO-03013527 (2003).
104. SCHERING CORP (Asberom T, Guzik HS, Josien HB, Pissamitski DA): Novel β-secretase inhibitors. WO-03014075 (2003).
105. SCHERING CORP/PHARMACOPEIA INC (Pissarnitski DA, Josien HB, Smith EM, Clader JW, Asberom T, Guo T, Hobbs DW): γ-Secretase inhibitors. WO-03066592 (2003).
106. MERCK SHARP & DOHME LTD/MERCK & CO INC (Brands KM, Davies AJ, Oakley PJ, Scott JP, Shaw DE, Teall MR): Synthesis of cyclohexanone derivatives. WO-2004013090 (2004).
107. MERCK SHARP & DOHME LTD (Castro Pineiro JL, Churcher I, Dinnell K, Harrison T, Kerrad S, Nadin AJ, Oakley PJ, Owens AP, Shaw DE, Teall MR, Williams BJ et al): Sulfones which modulate the action of γ secretase. WO-02081435 (2002).
108. MERCK SHARP & DOHME LTD(Churcher I, Dinnell K, Harrison T, Kerrad S, Nadin AJ, Oakley PJ, Shaw DE, Teall MR, Williams BJ, Williams S): Hovel cyclohexyl sulphones. WO-03018543 (2003).
109. MERCK SHARP & DOHME LTD (Harrison T, Oakley PJ, Teall MR): Sulfones which modulate the action of β-secretase. WO-02081433 (2002).
110. BAYER AG (Hendrix M, Baumann K, Grosser R, König G, Düsterhus V, Krüger J): Phenyl sulfoxides and phenyl sulfones. WO-03059335 (2003).
111. DAIICHI PHARMACEUTICAL CO LTD (Yasukochi T, Ito M, Kubota H, Miyauchi S, Saito M): β-Amyloid protein production/secretion inhibitors. WO-03055850 (2003).
112. ELI LILLY & CO/ELAN PHARMACEUTICALS INC (Audia JE, John V, Latimer LH, McDaniel SL, Nissen JS, Thorsett ED, Tung JS): Lactam compound. WO-00247671 (2002).
113. ELI LILLY & CO (Koenig TM, Mitchell D, Nissen JS): Lactam compound. WO-00240508 (2002).
114. ELI LILLY & CO (Koenig TM, Audia JE, Mitchell D, McDaniel SL, Buccilli LA, Engel GL, Aikins JA): Lactam compound. WO-00240451 (2002).
115. DUPONT PHARMACEUTICALS CO (Olson RE): Succinoylamino-benzodiazepines as inhibitors of Aβ protein production. WO-00038618 (2000).
116. DUPONT PHARMACEUTICALS CO (Olson RE, Maduskuie TP, Thomas LA): Succinoylamino lactams as inhibitors of Aβ protein production. WO-00007995 (2000).
117. DUPONT PHARMACEUTICALS CO (Zaczek, RC): Use of radioligands to screen inhibitors of β-amyloid peptide production. WO-00028331 (2000).